Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 411: Which of the following statements is true regarding zero-order kinetics?

A. Commonly seen in therapeutic doses of most drugs.
B. Follows a constant rate of elimination regardless of concentration. (Correct Answer)
C. Rate of elimination depends on drug concentration.
D. Occurs only at subtherapeutic doses of drugs.

Explanation: ***Follows a constant rate of elimination regardless of concentration.***[2] - In **zero-order kinetics**, a **constant amount** of drug is eliminated per unit of time, irrespective of the drug's plasma concentration.[2] - This occurs when the **elimination pathways** become **saturated**, meaning the enzymes or transporters responsible for elimination are working at their maximum capacity.[1, 2] - Classic examples include **phenytoin**, **aspirin** (at high doses), and **alcohol**.[1] *Commonly seen in therapeutic doses of most drugs.* - Most drugs at **therapeutic doses** follow **first-order kinetics**, where a **constant *fraction*** (not amount) of the drug is eliminated per unit of time.[1, 2] - This implies that the rate of elimination is **proportional** to the drug concentration.[1, 2] *Rate of elimination depends on drug concentration.* - This statement describes **first-order kinetics**, where the **rate of elimination** is directly proportional to the **drug concentration**.[1, 2] - In contrast, zero-order kinetics demonstrates a rate of elimination that is **independent** of concentration once saturation is reached.[1, 2] *Occurs only at subtherapeutic doses of drugs.* - This is **incorrect**. Zero-order kinetics typically occurs at **high doses** when elimination pathways become saturated, not at subtherapeutic doses.[1, 2] - At low concentrations, drugs generally follow **first-order kinetics**.

Question 412: A patient with hypercholesterolemia has a mutation in the LDL receptor gene. Evaluate the potential effect of statin therapy in this patient.

A. Decreased LDL receptor expression, increased cholesterol synthesis
B. Increased LDL receptor expression, increased cholesterol synthesis
C. Decreased LDL receptor expression, reduced cholesterol synthesis
D. Increased LDL receptor expression, reduced cholesterol synthesis (Correct Answer)

Explanation: ***Increased LDL receptor expression, reduced cholesterol synthesis*** - Statins **inhibit HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, leading to decreased intracellular cholesterol. - This reduction in intracellular cholesterol upregulates **LDL receptor gene expression** on hepatocyte surfaces through SREBP-2 pathway activation. - **Clinical Note**: In patients with LDL receptor mutations (familial hypercholesterolemia), statins still increase receptor expression and reduce cholesterol synthesis, but the upregulated receptors may be **non-functional or defective**, resulting in reduced therapeutic efficacy compared to patients with normal receptors. However, the molecular mechanisms described above still occur. *Decreased LDL receptor expression, increased cholesterol synthesis* - This describes a state of **cholesterol abundance** rather than the effects of statin therapy. - Increased intracellular cholesterol would typically lead to decreased LDL receptor expression and increased cholesterol synthesis through negative feedback. *Increased LDL receptor expression, increased cholesterol synthesis* - While statins do increase **LDL receptor expression**, they act by **inhibiting HMG-CoA reductase**, thereby **reducing cholesterol synthesis**. - This combination is contradictory and does not reflect statin pharmacology. *Decreased LDL receptor expression, reduced cholesterol synthesis* - Though statins **reduce cholesterol synthesis**, they simultaneously **increase LDL receptor expression** through compensatory upregulation in response to intracellular cholesterol depletion. - Decreased LDL receptor expression would counteract the beneficial effects of statin therapy on LDL clearance.

Question 413: What are the purposes of using epinephrine in conjunction with local anesthetics?

A. To prolong the duration of anesthesia
B. To decrease systemic absorption
C. To reduce bleeding
D. All of the options (Correct Answer)

Explanation: ***All of the options*** - Epinephrine is a **vasoconstrictor** that produces all three of the listed benefits when combined with local anesthetics. - The **vasoconstrictive effect** reduces blood flow at the injection site, which simultaneously achieves multiple therapeutic purposes. - All three mechanisms work together through a single pharmacological action: **local vasoconstriction**. **1. Prolongs the duration of anesthesia:** - Vasoconstriction reduces blood flow to the area, delaying the washout of the local anesthetic from the nerve site. - This maintains a higher local concentration of anesthetic for a longer period, extending the duration of nerve block. - Duration can be increased by 50-100% depending on the site and anesthetic used. **2. Decreases systemic absorption:** - By constricting local blood vessels, epinephrine slows the rate at which the local anesthetic enters the systemic circulation. - This reduces peak plasma concentrations, **lowering the risk of systemic toxicity** (CNS and cardiac effects). - Allows use of higher total doses of local anesthetic when needed. **3. Reduces bleeding:** - The vasoconstrictive effect directly narrows small blood vessels in the surgical field. - This **reduces capillary bleeding**, improving surgical visibility and decreasing blood loss during procedures. - Particularly useful in highly vascular areas like the oral cavity and scalp.

Question 414: A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

A. 15 mg
B. 8 mg
C. 12 mg
D. 10 mg (Correct Answer)

Explanation: ***10 mg*** - The **therapeutic index (TI)** is calculated as **LD50 / ED50**. - Given a TI of 5 and an ED50 of 2 mg, the LD50 = TI × ED50 = 5 × 2 mg = **10 mg**. - This is the correct application of the therapeutic index formula. *15 mg* - This value would imply a therapeutic index of 7.5 (15 mg / 2 mg), which is incorrect based on the given information. - Does not align with the definition and calculation of the therapeutic index. *8 mg* - This value would result in a therapeutic index of 4 (8 mg / 2 mg), not the given TI of 5. - Represents an incorrect application of the therapeutic index formula. *12 mg* - This value would yield a therapeutic index of 6 (12 mg / 2 mg), differing from the provided TI of 5. - Does not correctly reflect the relationship between ED50, LD50, and the therapeutic index.

Question 415: What is the primary concern regarding the dosing of statins in patients with hepatic impairment?

A. Potential for reduced efficacy due to altered metabolism
B. Increased risk of toxicity due to reduced clearance (Correct Answer)
C. Altered bioavailability due to first-pass metabolism
D. Need for mandatory dose reduction in all cases regardless of severity

Explanation: Increased risk of toxicity due to reduced clearance - Hepatic impairment significantly reduces the liver's ability to metabolize and clear statins from the body - This reduced clearance results in higher systemic exposure to the drug, increasing the risk of dose-dependent adverse effects such as myopathy and rhabdomyolysis [1] - The primary clinical concern is the increased toxicity risk, which necessitates careful dose adjustment and monitoring Potential for reduced efficacy due to altered metabolism - While metabolism may be altered, the primary concern is increased drug levels rather than reduced efficacy [2] - Most statins are metabolized to active or inactive metabolites, and hepatic impairment typically increases rather than decreases drug exposure [2] - Reduced efficacy is uncommon unless severe hepatic dysfunction prevents conversion of prodrug statins Need for mandatory dose reduction in all cases regardless of severity - Dose adjustment is not automatically required in all cases of hepatic impairment - Management depends on the severity of hepatic dysfunction (Child-Pugh class) and the specific statin used - Some statins (e.g., rosuvastatin, pravastatin) undergo minimal hepatic metabolism and may be safer options - The concern is toxicity risk, not blanket dose reduction Altered bioavailability due to first-pass metabolism - While first-pass metabolism can be altered in hepatic impairment, this typically results in increased bioavailability for highly extracted drugs [2] - Increased bioavailability would contribute to higher systemic exposure and toxicity, not a separate primary concern - The core issue remains overall drug accumulation and toxicity risk [1]

Question 416: A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

A. Lower therapeutic index, increased risk of toxicity (Correct Answer)
B. Higher therapeutic index, increased safety
C. Lower therapeutic index, unchanged efficacy
D. Higher therapeutic index, unchanged potency

Explanation: ***Lower therapeutic index, increased risk of toxicity*** - When the **therapeutic and toxic dose-response curves are closely positioned**, there is a narrow margin between the dose that produces therapeutic effects and the dose that causes toxicity - This narrow separation indicates a **low therapeutic index (TI = TD50/ED50)**, where TD50 (toxic dose) and ED50 (effective dose) are close in value - Clinically, this means **increased risk of toxicity** as small dose increases or patient variability can easily shift from therapeutic to toxic range - Examples include drugs like **digoxin, warfarin, and aminoglycosides** which require careful monitoring *Higher therapeutic index, increased safety* - This would be true if the toxic dose-response curve was **far separated** from the therapeutic curve on the dose axis - Close positioning of curves indicates **low, not high** therapeutic index - Higher therapeutic index drugs have a wide safety margin (e.g., penicillins, most NSAIDs) *Lower therapeutic index, unchanged efficacy* - While **lower therapeutic index** is correct, "unchanged efficacy" is not a relevant inference from curve positioning - **Efficacy** refers to the maximal effect (Emax), represented by the plateau height of the dose-response curve, not its position on the dose axis - Therapeutic index and efficacy are independent parameters *Higher therapeutic index, unchanged potency* - Close positioning of therapeutic and toxic curves indicates **lower, not higher** therapeutic index - **Potency** (dose required for effect, reflected by ED50 position) is independent of therapeutic index - A drug can be highly potent but have a low therapeutic index if toxic effects occur at doses close to therapeutic doses

Question 417: When comparing oral and intravenous routes of administration, which statement best describes the difference in bioavailability?

A. Oral has lower bioavailability due to prolonged absorption.
B. Intravenous has higher bioavailability due to rapid distribution.
C. Intravenous has higher bioavailability due to increased absorption.
D. Oral has lower bioavailability due to first-pass metabolism. (Correct Answer)

Explanation: ***Oral has lower bioavailability due to first-pass metabolism.*** - **Bioavailability** for orally administered drugs is typically reduced because a significant portion of the drug may be **metabolized by the liver** before reaching systemic circulation, known as **first-pass metabolism**. - This process decreases the amount of unmetabolized drug available to exert a **pharmacological effect** compared to direct intravenous administration. - **IV has 100% bioavailability** because the drug bypasses absorption barriers and first-pass metabolism entirely. *Oral has lower bioavailability due to prolonged absorption.* - While **prolonged absorption** can influence the **rate** at which a drug reaches systemic circulation, it does not inherently decrease the total amount of drug that eventually enters the bloodstream (**bioavailability**). - **Bioavailability** refers to the *fraction* of an administered dose that reaches systemic circulation **unchanged**. *Intravenous has higher bioavailability due to rapid distribution.* - **Intravenous (IV)** administration indeed results in **100% bioavailability** because the drug is directly introduced into the systemic circulation, bypassing absorption barriers and **first-pass metabolism**. - However, **rapid distribution** describes how quickly the drug spreads throughout the body from the bloodstream to various tissues, which impacts the **onset of action** rather than bioavailability itself. - Distribution does not determine bioavailability. *Intravenous has higher bioavailability due to increased absorption.* - This statement is **incorrect** because **IV administration bypasses absorption entirely** - the drug is delivered directly into the bloodstream. - **Absorption** refers to the process by which a drug enters the bloodstream from its site of administration (e.g., GI tract for oral drugs). - IV has 100% bioavailability because there is **no absorption phase**, not because of "increased absorption".

Question 418: What is the benefit of combining levodopa with carbidopa in the treatment of Parkinson's disease?

A. Enhances CNS penetration of levodopa
B. Reduces peripheral side effects of levodopa (Correct Answer)
C. Prolongs the half-life of levodopa
D. Increases dopamine receptor sensitivity

Explanation: ***Reduces peripheral side effects of levodopa*** - Carbidopa is a **dopa decarboxylase inhibitor** that does not cross the blood-brain barrier. It inhibits the peripheral conversion of levodopa to dopamine, thereby reducing peripheral side effects like **nausea**, **vomiting**, and **cardiac arrhythmias**. - By reducing peripheral metabolism, more levodopa is available to cross the **blood-brain barrier** and be converted to dopamine in the brain, improving therapeutic efficacy. *Enhances CNS penetration of levodopa* - Carbidopa itself **does not cross the blood-brain barrier**, so it cannot directly enhance the central nervous system (CNS) penetration of levodopa. - Its action is primarily in the **periphery**, preventing levodopa's premature conversion to dopamine before it reaches the brain. *Prolongs the half-life of levodopa* - While carbidopa increases the amount of levodopa available to the brain, it does not significantly **prolong the plasma half-life** of levodopa itself. - The primary effect is to **reduce peripheral metabolism**, allowing a greater proportion of the administered dose to reach the CNS. *Increases dopamine receptor sensitivity* - Carbidopa's mechanism of action involves **enzyme inhibition** (dopa decarboxylase) and does not directly affect the sensitivity of **dopamine receptors** in the brain. - Levodopa is converted to dopamine, which then acts on these receptors, but carbidopa does not modulate their sensitivity.

Question 419: A 30-year-old woman requires drug administration with 100% bioavailability. Which of the following routes will ensure this requirement?

A. Intravenous (Correct Answer)
B. Oral
C. Subcutaneous
D. Intramuscular

Explanation: ***Intravenous*** - **Intravenous (IV)** administration delivers the drug directly into the **bloodstream**, bypassing all absorption barriers and **first-pass metabolism**, ensuring **100% bioavailability by definition**. - This is the **only route** (along with intra-arterial) that guarantees complete bioavailability since the entire drug dose reaches systemic circulation. - Provides immediate and precise control over drug plasma levels. *Oral* - **Oral administration** is subject to significant **first-pass metabolism** in the liver and gastrointestinal degradation, leading to bioavailability **less than 100%**. - The drug must pass through the GI tract and undergo hepatic metabolism before reaching systemic circulation, which reduces the amount of active drug available. *Subcutaneous* - **Subcutaneous (SC)** administration requires absorption from the fatty tissue under the skin, which can be **slow and incomplete**, resulting in bioavailability **less than 100%**. - Factors like blood flow to the injection site, drug solubility, and molecular size significantly affect absorption. *Intramuscular* - **Intramuscular (IM)** administration generally provides good bioavailability (often 80-90%), but it is **rarely 100%** due to the need for absorption from muscle tissue into the bloodstream. - The rate and extent of absorption depend on muscle blood flow, injection site, and drug formulation.

Question 420: A pharmacokinetic study of a new drug reveals that it follows first-order kinetics. What does this imply about the drug's elimination?

A. A constant amount of drug is eliminated per unit time
B. A constant fraction of drug is eliminated per unit time (Correct Answer)
C. The drug has a variable half-life
D. The drug accumulates in the body over time

Explanation: ***A constant fraction of drug is eliminated per unit time*** - In **first-order kinetics**, the rate of drug elimination is directly proportional to the drug concentration [1]. - This means that a **constant percentage** or **fraction** of the drug is removed from the body per unit of time, regardless of the absolute amount present [2]. *A constant amount of drug is eliminated per unit time* - This describes **zero-order kinetics**, where the elimination pathways are saturated, and a fixed amount of drug is eliminated per unit of time [2]. - This is typical for drugs like **ethanol** at higher concentrations or **phenytoin** at therapeutic doses [1]. *The drug has a variable half-life* - Drugs following **first-order kinetics** have a **constant half-life**, meaning the time it takes for half of the drug to be eliminated from the body remains the same regardless of the initial concentration. - A variable half-life is more characteristic of **zero-order kinetics**, as the time to eliminate half the drug would depend on the current drug concentration. *The drug accumulates in the body over time* - While accumulation can occur with any drug if the dosing interval is too short or the dose is too high relative to elimination, **first-order kinetics** itself does not inherently imply accumulation if dosed appropriately. - Accumulation is more problematic with **zero-order kinetics** because the elimination rate does not increase with concentration, leading to a higher risk of toxicity.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free